Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group

References

• Draube A, Behringer K, Diehl V. German Hodgkin's Lymphoma Study Group trials: lessons from the past and current strategies. Clin Lymphoma Myeloma 2006;6:458–468.
   PubMedGoogle Scholar
• Diehl V, Klimm B, Re D. Hodgkin lymphoma: a curable disease: what comes next? Eur J Haematol Suppl 2005;66:6–13.
   PubMedGoogle Scholar
• Ng AK, Mauch PM. Late complications of therapy of Hodgkin's disease: prevention and management. Curr Hematol Rep 2004;3:27–33.
   PubMedGoogle Scholar
• Mauch P, Ng A, Aleman B, Report from the Rockefeller Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9–16, 2003, Bellagio, Italy. Eur J Haematol Suppl 2005;66:68–76.
   PubMedGoogle Scholar
• van Leeuwen FE, Klokman WJ, Stovall M, Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003;95:971–980.
   PubMed Web of Science ®Google Scholar
• Engert A, Plutschow A, Eich HT, Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640–652.
   PubMed Web of Science ®Google Scholar
• Ferme C, Eghbali H, Meerwaldt JH, Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007;357:1916–1927.
   PubMed Web of Science ®Google Scholar
• Carde P, Koscielny S, Franklin J, Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol 2002;13(Suppl. 1):86–91.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Fiore F, Sorasio R, Meignan M. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk Lymphoma 2009;50:1761–1764.
   PubMed Web of Science ®Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630–1636.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506–1514.
   PubMed Web of Science ®Google Scholar
• Meyer RM, Gospodarowicz MK, Connors JM, Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634–4642.
   PubMed Web of Science ®Google Scholar
• Klimm B, Engert A. Combined modality treatment of Hodgkin's lymphoma. Cancer J 2009;15:143–149.
   PubMed Web of Science ®Google Scholar
• Yahalom J. Changing role and decreasing size: current trends in radiotherapy for Hodgkin's disease. Curr Oncol Rep 2002;4:415–423.
   PubMedGoogle Scholar
• Yahalom J. Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur J Haematol Suppl 2005;66:90–97.
   PubMedGoogle Scholar
• Nieder C, Schill S, Kneschaurek P, Molls M. Comparison of three different mediastinal radiotherapy techniques in female patients: impact on heart sparing and dose to the breasts. Radiother Oncol 2007;82:301–307.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, Berthelsen AK, Specht L. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol 2007;78:206–212.
   PubMed Web of Science ®Google Scholar
• Eich HT, Engenhart-Cabillic R, Hansemann K, Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin's lymphoma: an analysis of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 2008;71:1419–1424.
   PubMed Web of Science ®Google Scholar
• Eich HT, Gossmann A, Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 2004;58:1121–1127.
   PubMed Web of Science ®Google Scholar
• Kinzie JJ, Hanks GE, MacLean CJ, Kramer S. Patterns of care study: Hodgkin's disease relapse rates and adequacy of portals. Cancer 1983;52:2223–2226.
   PubMed Web of Science ®Google Scholar
• Diez P, Hoskin PJ, Aird EG. Treatment planning and delivery of involved field radiotherapy in advanced Hodgkin's disease: results from a questionnaire-based audit for the UK Stanford V regimen vs ABVD clinical trial quality assurance programme (ISRCTN 64141244). Br J Radiol 2007;80:816–821.
   PubMed Web of Science ®Google Scholar
• Girinsky T, van der Maazen R, Specht L, Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006;79:270–277.
   PubMed Web of Science ®Google Scholar
• Hirsch A, Vander Els N, Straus DJ, Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 1996;14:1297–1305.
   PubMed Web of Science ®Google Scholar
• Marina NM, Greenwald CA, Fairclough DL, Serial pulmonary function studies in children treated for newly diagnosed Hodgkin's disease with mantle radiotherapy plus cycles of cyclophosphamide, vincristine, and procarbazine alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Cancer 1995;75:1706–1711.
   PubMed Web of Science ®Google Scholar
• Evens AM, Cilley J, Ortiz T, G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007;137:545–552.
   PubMed Web of Science ®Google Scholar
• Longo DL. Radiation therapy in Hodgkin disease: why risk a Pyrrhic victory? J Natl Cancer Inst 2005;97:1394–1395.
   PubMed Web of Science ®Google Scholar
• Rueda Dominguez A, Marquez A, Guma J, Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 2004;15:1798–1804.
   PubMed Web of Science ®Google Scholar
• Straus DJ, Portlock CS, Qin J, Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004;104:3483–3489.
   PubMed Web of Science ®Google Scholar
• De Bruin ML, Sparidans J, van't Veer MB, Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009;27:4239–4246.
   PubMed Web of Science ®Google Scholar
• Goda JS, Tsang RW. Involved field radiotherapy for limited stage Hodgkin lymphoma: balancing treatment efficacy against long-term toxicities. Hematol Oncol 2009;27:115–122.
   PubMed Web of Science ®Google Scholar
• Wirth A, Kron T, Wittwer H, Sullivan K, Sorell G, Cramb J. Phantom measurements and computed estimates of breast dose with radiotherapy for Hodgkin's lymphoma: dose reduction with the use of the involved field. J Med Imaging Radiat Oncol 2008;52:394–402.
   PubMed Web of Science ®Google Scholar
• Shahidi M, Kamangari N, Ashley S, Cunningham D, Horwich A. Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. Radiother Oncol 2006;78:1–5.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Hutchings M, Rigacci L, Early interim 2-[18F].fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746–3752.
   PubMed Web of Science ®Google Scholar
• Re A, Ferrari S, Frata P, Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study. Ann Oncol 2008;19:951–957.
   PubMed Web of Science ®Google Scholar
• Radford J, O'Doherty M, Barrington S, Results of the 2nd planned interim analysis of the RAPID trial in patients with clinical stages IA and IIA Hodgkin lymphoma and a FDG-PET scan after 3 cycles ABVD. Blood 2008;112(Suppl. 1): Abstract 369.
   PubMed Web of Science ®Google Scholar
• Eich HT, Diehl V, Gorgen H, Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 Trial. J Clin Oncol 2010;28:4199–4206.
   PubMed Web of Science ®Google Scholar
• Noordijk E, Thomas J, Ferme C, First results of the EORTC-GELA H9 randomised trials: the H9-F trial comparing 3 radiation dose levels and the H9-U trial comparing 3 chemotherapy schemes in patients with favorable or unfavorable early stage Hodgkin lymphoma. J Clin Oncol 2005;23(Suppl.):561s.
   Google Scholar
• Borchmann P, Engert A, Pluetschow A, Dose intensified combined modality treatment with 2 cycles of BEACOPP escaltaed followed by 2 cycles of ABVD and involved field radiotherapy is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma: an analysis of the German Hodgkin Study group HD14 trial. Blood 2008;112(Suppl. 1): Abstract 367.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005;16:1160–1168.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Fanti S, Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 2006;17:1296–1300.
   PubMed Web of Science ®Google Scholar
• Colonna P, Jais JP, Desablens B, Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. J Clin Oncol 1996;14:1928–1935.
   PubMed Web of Science ®Google Scholar
• Iannitto E, Minardi V, Gobbi PG, Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. Clin Lymphoma Myeloma 2009;9:138–144.
   PubMedGoogle Scholar